Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies

Medtronic plans to acquire Contego Medical for $380 million, expanding its carotid artery disease treatment portfolio. The deal includes Contego's FDA-approved Neuroguard IEP™ Direct System. Medtronic expects the acquisition to be minimally dilutive to adjusted EPS in FY27 and FY28, and neutral to accretive thereafter. The transaction is subject to closing conditions and expected to complete in Q3 FY25.

Original reporting
Published Nov 17, 2026, 6:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 10:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medtronic buys Contego Medical for $380 M, expanding access to next-generation carotid therapies — source image
Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

The acquisition adds Contego’s recently FDA-approved Neuroguard IEP Direct System, described as the first and only TCAR-IEP system with integrated embolic protection plus flow reversal, expanding Medtronic’s differentiated carotid technology portfolio.

02

Market read

Traders can reassess MDT’s deal-driven valuation and near-term EPS risk given the stated $380M price, expected Q3 FY closing, and EPS dilution/accretion profile.

03

What to watch

Closing conditions, regulatory/competitive review timing, and whether Neuroguard IEP adoption ramps faster or slower than expected could dominate the stock reaction more than the headline valuation.

Relevance 8/10Novelty 8/10Timing: deal completion expected in Medtronic fiscal Q3, subject to customary closing conditions

Background

Contego Medical is a privately held device maker focused on carotid artery disease and peripheral thrombectomy, with an exclusive US distribution agreement with Medtronic announced in January 2025.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Medtronic announces intent to acquire Contego Medical for $380M, adding the FDA-approved Neuroguard IEP Direct System to its carotid portfolio.

Expected impact

Likely modest upside bias as investors price in portfolio expansion and potential EPS neutrality after FY28, tempered by deal-risk and integration uncertainty.

Evidence & confidence

The article provides deal value ($380M), timing (Q3 FY), and EPS dilution/accretion expectations, which are direct inputs for valuation and risk assessment.

Market effects

Could strengthen competitive positioning in carotid revascularization and embolic protection devices, potentially increasing M&A and product-cycle focus in vascular intervention.

US-focused distribution and FDA-approved system may shift near-term demand expectations for TCAR-IEP adoption in the US.

If the technology scales beyond the US, it may influence global vascular intervention competitive dynamics and procurement preferences.

Counterpoint

Investors may discount the strategic value if the acquisition is only minimally dilutive near-term and accretive later, implying limited immediate earnings lift.

Key entities

  • Medtronic

    US-listed healthcare technology company announcing intent to acquire Contego Medical for $380M.

  • Contego Medical

    Privately held medical device company developing integrated embolic protection for TCAR-IEP, including Neuroguard IEP Direct System.

  • Neuroguard IEP Direct System

    Recently FDA-approved transcarotid artery revascularisation system with integrated embolic protection and flow reversal.

Related articles

$MDTMed

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Medtronic (NYSE: MDT) received FDA clearance for its Hugo™ robotic-assisted surgery system to perform general surgery procedures, including cholecystectomy and hernia repairs. The expansion covers 3.5 million annual U.S. surgeries. The system's modular design offers flexibility, and Medtronic aims to surpass 50,000 procedures globally by its fiscal year-end.

$MDTMedAI 9/10

Medtronic agrees to buy carotid stent maker Contego Medical for $380 million

Medtronic agreed to acquire Contego Medical for $380 million, with potential additional payments. The deal includes Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices. Medtronic expects the acquisition to close in its fiscal third quarter, with minimal EPS dilution in fiscal 2027 and 2028, and a neutral to accretive effect afterward. Contego's devices focus on carotid artery disease and peripheral thrombectomy.

$MDTMedAI 8/10

Medtronic to buy Contego Medical for $380M

Medtronic plans to acquire Contego Medical, a privately held medical device company, for $380 million. The deal will expand Medtronic's carotid disease treatments and is expected to close in Q3 of its fiscal year. Medtronic expects minimal dilution to earnings in fiscal 2027 and 2028, then neutrality or accretion after that.